Sirolimus by OrphAI Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.

Source link
#Sirolimus #OrphAI #Therapeutics #Pulmonary #Arterial #Hypertension #Likelihood #Approval